Oppenheimer Initiates Coverage On Cormedix with Outperform Rating, Announces Price Target of $15
CorMedix Inc CRMD
$7.85
▲ +1.03%
(+$0.08)
⬆️ Above Yest. High
🔥 High Short Interest
Open
$7.79
Prev Close
$7.77
Day Range
$7.69 – $7.90
52W Range
$6.13 – $13.02
Market Cap
$605.63M
P/E (TTM)
3.24
Beta
1.45
EPS (TTM)
$2.10
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2010-03-25 |
| Shares Out. | 78,450,000 |
| Website | cormedix.com/ ↗ |
| Phone | 13026365400 |
| Employees | 191 |
| Revenue | $101.9M |
| Gross Profit | $77.1M |
| Net Income | $26.0M |
| Free Cash Flow | $250.4M |
| Total Assets | $904.1M |
| Total Liabilities | $443.2M |
| Equity | $460.8M |
About CorMedix Inc
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
CorMedix Inc is a publicly traded company under the ticker symbol CRMD on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-09-01)